Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
$18.5M Buy
408,712
+235,425
+136% +$10.4M 0.06% 265
2017
Q1
$7.37M Buy
173,287
+8,549
+5% +$349K 0.03% 393
2016
Q4
$6.61M Sell
164,738
-1,291
-0.8% -$49.8K 0.03% 397
2016
Q3
$6.45M Buy
166,029
+1,795
+1% +$67.8K 0.02% 394
2016
Q2
$5.68M Buy
164,234
+31,130
+23% +$1.08M 0.02% 403
2016
Q1
$4.59M Buy
133,104
+48,515
+57% +$1.69M 0.02% 433
2015
Q4
$3.09M Buy
84,589
+1,436
+2% +$55.9K 0.01% 500
2015
Q3
$3.25M Hold
83,153
0.01% 444
2015
Q2
$3.17M Sell
83,153
-2,073
-2% -$72.6K 0.01% 457
2015
Q1
$2.81M Buy
+85,226
New +$2.62M 0.01% 487

Other funds holding HOLX

Aberdeen Asset Management's HOLX Position: Q2 2017 in Review

Aberdeen Asset Management increased its Hologic (HOLX) stake by 136% in Q2 2017, buying an estimated $10.4M and bringing the position to 408,712 shares worth $18.5M. The position accounts for 0.06% of the portfolio, ranked #265.

Aberdeen Asset Management first reported a position in HOLX in Q1 2015 and has held it in 10 quarters since. 505 funds tracked by Wall St. Rank hold HOLX as of Q2 2017.

  • Aberdeen Asset Management held 408,712 shares of Hologic worth $18.5M as of Q2 2017.
  • Aberdeen Asset Management bought 235,425 Hologic shares in Q2 2017, an estimated $10.4M.
  • Hologic made up 0.06% of Aberdeen Asset Management's portfolio in Q2 2017, its #265 holding.
  • Aberdeen Asset Management first reported a position in Hologic in Q1 2015 and has held it in 10 quarters since.
  • 505 funds tracked by Wall St. Rank held Hologic as of Q2 2017.

Based on Aberdeen Asset Management's 13F filing for Q2 2017, filed 10 Aug 2017.